Financials data is unavailable for this security.
View more
Year on year Celldex Therapeutics Inc had net income fall 25.91% from a loss of 112.33m to a larger loss of 141.43m despite a 192.02% increase in revenues from 2.36m to 6.88m.
Gross margin | -- |
---|---|
Net profit margin | -1,809.40% |
Operating margin | -2,117.45% |
Return on assets | -26.24% |
---|---|
Return on equity | -27.53% |
Return on investment | -27.27% |
More ▼
Cash flow in USDView more
In 2023, Celldex Therapeutics Inc increased its cash reserves by 18.30%, or 5.39m. Cash Flow from Financing totalled 218.46m or 3,173.88% of revenues. In addition the company used 107.29m for operations while cash used for investing totalled 105.78m.
Cash flow per share | -2.62 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 12.28 |
---|---|
Tangible book value per share | 11.87 |
More ▼
Balance sheet in USDView more
Current ratio | 29.36 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼